Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Co-Leads $16 Million Round in Yaoshibang, a Mobile Pharmacy App

publication date: Feb 8, 2017

Fosun Group co-led an $16 million Series B round in Yaoshibang, a Guangzhou-based mobile app that provides online pharmacy services. The fund was co-led by Green Pine Capital Partners of Shenzhen. Yaoshibang's mobile app allows individuals to order medicines directly from off-line pharmacies, with guaranteed next-day delivery in major cities. Currently, the two-year-old start-up operates in over 40 cities in China, and has over 50,000 pharmacies signed onto the platform.  It plans to use the proceeds to build its platform and expand market share. Existing investors Co-Power Capital Management Co., Ltd. and Ivy Capital also participated in the round. More details....

Stock Symbol (HK:656)

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital